Table 1 Demographic and clinical outcomes for intensive care patients with hVISA and VSSA bacteraemia^a

Patient demographics

 Median age (years)

71.4 ± 16.9

69.7 ± 12.3

0.76

 Male sex

9 (64.3)

18 (52.9)

0.47

Comorbidity

 Chronic renal disease

5 (35.7)

13 (38.2)

0.87

 Solid organ malignancy

3 (21.4)

5 (14.7)

0.57

 Hematological malignancy

1 (7.1)

1 (2.9)

0.508

 Diabetes mellitus

4 (28.6)

14 (41.2)

0.412

 Liver cirrhosis

4 (28.6)

5 (14.7)

0.263

 Heart disease

1 (7.1)

8 (23.5)

0.186

 Chronic pulmonary disease

1 (7.1)

1 (2.9)

0.508

 Cerebrovascular accident

2 (14.3)

10 (29.4)

0.271

Primary site of infection

0.045

 Catheter-related infection

1 (7.1)

6 (17.6)

 Pneumonia

6 (42.9)

18 (52.9)

 Surgical wound infection

0

3 (8.8)

 Other

0

3 (8.8)

 Unknown

7 (50)

4 (11.8)

CRP

147.3 ± 11.3

132.6 ± 75.6

0.62

Albumin

2.5 ± 0.5

2.5 ± 0.6

0.82

Charlson comorbidity score

2.7 ± 1.6

3.1 ± 2.1

0.307

SOFA score

8 ± 3.2

8.4 ± 4.1

0.774

Prior vancomycin therapy

5 (35.7)

10 (29.4)

0.669

Adequate antibiotics treatment

3

12

0.279

Hemodialysis

7

14

0.403

Shock after infection

4

13

0.386

Outcomes

 In-hospital mortality

13 (92.9)

22 (64.7)

0.046

 Attributable mortality by MRSA bacteremia

6 (42.9)

14 (41.2)

0.915

 Length of stay in hospital after MRSA bacteremia (days)

32.6 ± 34.4

33.4 ± 49.3

0.96

 Length of stay in ICU after MRSA bacteremia (days)

27.7 ± 31.5

21.2 ± 45.9

0.629

 Admission days to first culture

44.5 ± 48.3

27.0 ± 20.5

0.083